The National Alliance of State & Territorial AIDS Directors (NASTAD) released “Strategies to Increase Access to Hepatitis C (HCV) Treatment within ADAPs: Provider Decision Tree,” an interactive and web-based resource to support AIDS Drug Assistance Programs (ADAPs) in communicating their role in securing access to HCV treatment to providers. Produced as part of NASTAD’s cooperative agreement with the Health Resources and Services Administration (HRSA), this resource outlines treatment coverage options available to people living with HIV and HCV, including ADAP. It was first released as a printable PDF in July 2018.
While many ADAPs cover directly acting antiviral (DAA) HCV medications in instances in which other payers (e.g., Medicaid, private insurance) deny coverage, the broader health care landscape remains confusing for clients and providers to navigate. Many providers do not maximize all available treatment opportunities, instead relying solely on pharmaceutical companies’ patient assistance and cost-sharing assistance programs. ADAPs should share this resource with local HIV/HCV service providers, including those who work outside of the Ryan White HIV/AIDS Program (RWHAP).
